SOURCE: Vivakor, Inc.

February 08, 2010 08:00 ET

Vivakor Announces the Launch of Its Second Generation VivaThermic Cryovials Designed Specifically for Stem Cell Research

CORALVILLE, IA--(Marketwire - February 8, 2010) - Vivakor, Inc. (OTCBB: VIVK) announced the development of its second generation VivaThermic Cryovials. The VivaThermic 2.0 cryovials were specifically designed to facilitate improved cryopreservation of induced Pluripotent Stem cells (iPS cells) and protein-induced Pluripotent Stem cells (piPS). Their use and the ability to cryogenically preserve these cells is a critical and integral part of the most important type of stem research going on today. These cells, as well as human embryonic stem cells, have been shown to be particularly difficult to manage in the cryopreservation process. The VivaThermic 2.0 vials were created to improve cell survival and recovery rates of these cell types, while maintaining the desired differentiative state (i.e., ability to be grown or developed into different types of tissue). Successful long-term preservation of stem cells requires in-depth knowledge of physical, thermodynamical and chemical parameters and their mutual interactions. The currently applied method for cryopreservation of "clumped" iPS cells is not standardized and has a low efficiency: the survival rates after thawing are lower than 10% and the reproducibility of the results is very low. These new vials may hold the answer to this critical issue facing the stem cell research market today. As such they represent a dramatic leap forward for Vivakor and stem cell research in general.

Vivakor CEO and Chief Scientific officer, Dr. Tannin Fuja, commented on the value of this new technology: "With this innovation, Vivakor and its VivaThermic vials are now poised to take a leadership position in the stem cell preservation field both from a research technology as well as a market share perspective." More information about the vials and their use may be found at the company's website at

About Vivakor

Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at


This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information

  • Contact:
    Vivakor Investor Relations
    c/o IME Advisors
    (888) 648-8485